EMA confirms risk benefit of Multaq - 22-Sep-2011

EMA has confirmed a positive benefit-risk balance for Multaq (dronedarone) from Sanofi- Aventis for the treatment of a newly defined population of paroxysmal and persistent Atrial Fibrillation patients, following its review under the Article 20 procedure. A new indication for Multaq is: indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation.

Related News

Related Cardiology Information

Related Cardiology Drugs

Back to top

Latest News

10 May 2015
20 May 2013
20 May 2013